News | Radiopharmaceuticals and Tracers | August 30, 2017

Strategic partnership will support production and processing of radioisotopes on GE’s PETtrace 800 medical cyclotron platform

ARTMS Products Inc. and GE Healthcare Team Up to Expand Cyclotron-Produced Radioisotopes

August 30, 2017 — ARTMS Products Inc. signed a strategic partnership with GE Healthcare around ARTMS’ proprietary QUANTM99 Irradiation System (QIS) for radioisotope production. The goal of the partnership is to supply equipment, technologies and research that supports the production and processing of radioisotopes on GE’s PETtrace 800 platform of medical cyclotrons. The QIS integrates on to the GE PETtrace 800 series cyclotron to enable an alternative, non-reactor supply of valuable medical isotopes including technetium-99m, copper-64, gallium-68 and zirconium-89.

The strategic partnership includes an agreement for ARTMS to supply and install Europe’s first QUANTM system and research into expanding the number of available isotopes produced on GE’s PETtrace 800 series medical cyclotrons. ARTMS will work with GE to optimize the production and processing of isotopes such as copper-64 and gallium-68.

Every year Tc-99m is used in over 80 percent of all nuclear medicine imaging procedures in areas such as cardiology, oncology and neurology. Recently, Tc-99m produced with the QUANTM system was used to complete a Canadian multi-centre registration trial in bone imaging and thyroid function.

In the future, it is the intent of ARTMS and GE to continue to offer the QUANTM system to new and existing PETtrace cyclotron customers on a global basis.

The QUANTM technology includes all the required products and procedures for the production of Tc-99m using GE’s PETtrace cyclotrons and enables the production of other valuable isotopes through the bombardment of a high-energy proton beam against specific chemical ‘targets’.

The ARTMS process provides a cost-effective alternative to reactor-based technology. The technology produces no long-lived radioactive waste and advances efforts to eliminate the use of weapons-grade highly enriched uranium (HEU) in radioisotope production around the world.

For more information: www.gehealthcare.com, www.artmsproducts.com

Related Content

News | Radiopharmaceuticals and Tracers

May 16, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time May 16, 2022
arrow
News | Contrast Media

May 13, 2022 — The ACR Committee on Drugs and Contrast Media, within the ACR Commission on Quality and Safety, is aware ...

Time May 13, 2022
arrow
News | Nuclear Imaging

May 9, 2022 — Novartis announced a temporary, voluntary suspension of production at its radioligand therapy production ...

Time May 09, 2022
arrow
News | Proton Therapy

May 5, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology and the ...

Time May 05, 2022
arrow
News | Coronavirus (COVID-19)

May 4, 2022 — While the COVID-19 pandemic transitions through various phases, nuclear cardiology teams should maintain a ...

Time May 04, 2022
arrow
News | Quality Assurance (QA)

May 3, 2022 — Sun Nuclear Corporation, a wholly-owned subsidiary of Mirion Technologies, Inc., today announced the ...

Time May 03, 2022
arrow
News | Radiopharmaceuticals and Tracers

April 22, 2022 — A commonly used radioisotope, technetium-99m, used in medical diagnoses regularly suffers from ...

Time April 22, 2022
arrow
News | Prostate Cancer

April 15, 2022 — Prostate cancer is the most common malignant tumor in men in Germany, with about 62,000 new cases ...

Time April 14, 2022
arrow
News | Nuclear Imaging

April 13, 2022 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the American Society of Nuclear ...

Time April 13, 2022
arrow
News | PET-CT

April 11, 2022 — A novel nuclear medicine combination therapy has been proven safe and effective in men with heavily pre ...

Time April 11, 2022
arrow
Subscribe Now